CLOs on the Move

Santaris Pharma A/S USA

www.santaris.com

 
Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.santaris.com
  • 12626 High Bluff Dr Ste 440
    San Diego, CA USA 92130
  • Phone: 858.764.7064

Executives

Name Title Contact Details

Similar Companies

CannaPharmaRx

Headquartered in Carney's Point, New Jersey, CannaPharmaRx is a pharmaceutical company whose mission is to advance cannabinoid discovery, science, research & development, and to bring novel prescription, veterinary and personal care cannabinoid-based products to market in the U.S. and worldwide.

Sarnova

Sarnova is the leading national specialty distributor of healthcare products in the emergency medical services (EMS) and acute care markets. The company is comprised of four major business units: Bound Tree Medical, DXE Medical, Emergency Medical ...

Meier Clinics

Meier Clinics provides Christian counseling for those struggling with depression, anxiety, marriage issues, grief, ADD or ADHD, bipolar, and a variety of other issues.

Veranex

Veranex transforms your MedTech innovation with solutions for medical device, diagnostic, precision medicine, digital health, and drug delivery technologies.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.